孟鲁司特钠联合丙酸氟替卡松雾化吸入治疗儿童咳嗽变异性哮喘的疗效观察  

Efficacy Observation of Montelukast Sodium Combined with Fluticasone Propionate Inhalation in the Treatment of Cough-Variant Asthma in Children

作　　者：李娟 邱雯莉 LI Juan;QIU Wenli(Putian Overseas Chinese HospitalPharmacy Department,Putian 351111,China;Jiangsu Province Hospital of TCMradiology department,Nanjing 210000 China)

机构地区：[1]莆田华侨医院药剂科,福建莆田351111 [2]江苏省中医院放射科,江苏南京210000

出　　处：《中华灾害救援医学》2025年第1期86-89,共4页Chinese Journal of Disaster Medicine

摘　　要：目的 探讨孟鲁司特钠联合丙酸氟替卡松雾化吸入治疗咳嗽变异性哮喘的临床疗效。方法 回顾性分析2021年1月至2024年1月莆田华侨医院收治的80例咳嗽变异性哮喘患儿的临床资料,以治疗方案为分组依据,将患儿分为观察组(孟鲁司特钠+丙酸氟替卡松鼻喷雾剂雾化吸入,40例)和对照组(丙酸氟替卡松鼻喷雾剂雾化吸入,40例)。比较两组患儿临床疗效、肺功能指标、气道重塑指标、炎症指标、不良反应发生情况。结果 与对照组相比,观察组患儿的临床总有效率明显更高(P<0.05)。治疗前,两组患儿肺功能相关指标[用力肺活量(FVC)、最大呼气流量(PEF)、第1秒用力呼气容积(FEV1)]、气道重塑相关指标[气道管腔面积(LA)、气道管壁面积(WA)、气道总面积(TA)]、炎症指标[白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、嗜酸性粒细胞(EOS)]水平均无显著差异(P>0.05)。治疗后,两组患儿FVC、PEF、FEV1、LA、IL-10水平均显著提高(P<0.001),WA、TA、IL-4、EOS水平均显著降低(P<0.05);且与对照组患儿相比,观察组患儿FVC、PEF、FEV1、LA、TA、IL-10水平明显更高(P<0.05),WA、IL-4、EOS水平明显更低(P<0.001)。治疗期间,观察组患儿不良反应发生率与对照组无显著差异(P>0.05)。结论 对于咳嗽变异性哮喘患儿,孟鲁司特钠联合丙酸氟替卡松雾化吸入的治疗方案,临床疗效显著,能有效改善患儿肺功能,缓解患儿气道炎症,抑制患儿的气道重塑,且不良反应发生风险较低。Objective This study aims to investigate the clinical efficacy of nebulized montelukast sodium tablets combined with fluticasone propionate in the treatment of cough variant asthma.Methods A retrospective analysis was conducted on the clinical data of 80 children diagnosed with cough variant asthma at Putian Overseas Chinese Hospital from January 2021 to January 2024.Based on the treatment regimen,the children were divided into an observation group(montelukast sodium+nebulized fluticasone propionate,40 cases)and a control group(nebulized fluticasone propionate,40 cases).Clinical efficacy,pulmonary function parameters,airway remodeling indicators,inflammatory markers,and adverse event occurrences were compared between the two groups.Results The overall clinical efficacy rate in the observation group was significantly higher than that in the control group(P<0.05).Prior to treatment,there were no significant differences in pulmonary function parameters[forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume in one second(FEV1)],airway remodeling indicators[lumen area(LA),wall area(WA),total airway area(TA)],or inflammatory markers[interleukin-4(IL-4),interleukin-10(IL-10),eosinophils(EOS)]between the two groups(P<0.05).Post-treatment,both groups exhibited significant improvements in FVC,PEF,FEV1,LA,and IL-10 levels(P<0.001),while WA,TA,IL-4,and EOS levels significantly decreased (P<0.05). Furthermore, the observation group showed notably higher levels of FVC, PEF, FEV1, LA, TA, and IL-10 (P<0.05) and significantly lower levels of WA, IL-4, and EOS compared to the control group (P<0.001). The incidence of adverse reactions during treatment did not differ significantly between the observation and control groups (P>0.05). Conclusion The treatment regimen of nebulized montelukast sodium combined with fluticasone propionate demonstrates significant clinical efficacy in children with cough variant asthma. This combination effectively improves pulmonary function, alleviates airway inflammation, inhibi

关 键 词：哮喘 儿童 孟鲁司特钠 

分 类 号：R562.25[医药卫生—呼吸系统]